Find your next paid study

ModeX Therapeutics, An OPKO Health CompanyNCT06239194

Actual pay is set by the research site.

Gynecologic CancerCarcinomaUterine Cancer+1 more

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-cl…

University of Alabama at BirminghamNCT05559879

~$150 – $3,000

Actual pay is set by the research site.

Phase 4

Mechanistic Randomized Controlled Feasibility Trial of Aspirin on Endometrium and Inflammatory Metabolites in Postmenopausal Women With Non-Atrophic Endometrial Changes

This phase IV trial studies whether low dose aspirin can be used to lower inflammation and prevent endometrial cancer in postmenopausal women with changes in t…

Endometrial Carcinoma

~$25 – $1,000

Actual pay is set by the research site.

Mayo ClinicNCT07281547

Malignant Female Reproductive System NeoplasmRecurrent Cervical CarcinomaRecurrent Endometrial Carcinoma+22 more

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patien…

Platinum-resistant Ovarian CancerTesticular CancerEndometrial Cancer

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-eng…

Context Therapeutics Inc.NCT06515613

Actual pay is set by the research site.

Phase 2

UPLifT-Endo: Uterine Preservation Via Lifestyle Transformation A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Atypical Endometrial Hyperplasia or Grade 1 Endometrial Cancer

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up…

Endometrial HyperplasiaGrade 1 Endometrial Cancer

Washington University School of MedicineNCT05903131

~$75 – $2,000

Actual pay is set by the research site.

Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitum…

Novartis PharmaceuticalsNCT04104776

Actual pay is set by the research site.

Observational

Menstrual Cup-based Endometrial Collection as an Alternative to Endometrial Biopsy in Lynch Syndrome Patients

Study Goal: This pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (call…

Endometrial CancerLynch SyndromeScreening+1 more

Jessica D. St. Laurent, MDNCT07220239

~$10 – $1,125

Actual pay is set by the research site.

Colorectal CarcinomaEndometrial CarcinomaMelanoma+19 more

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come b…

Ovary CancerEndometrial CancerUterine Cancer

~$150 – $4,500

Actual pay is set by the research site.

Observational

The Impact of Alternate Day Fasting After Surgery for Patients Undergoing chemoTherapy (FAST Study)

Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of che…

Northwestern UniversityNCT05990426

~$10 – $750

Actual pay is set by the research site.

Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with…

Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more

Phase 2

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ov…